Diagnostic performance of serum mac-2-binding protein glycosylation isomer as a fibrosis biomarker in non-obese and obese patients with MASLD DOI Creative Commons
Prooksa Ananchuensook,

Kamonchanok Moonlisarn,

Bootsakorn Boonkaew

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 25, 2024

Abstract Aim Serum mac-2-binding protein glycosylation isomer (M2BPGi) is a new biomarker for liver fibrosis. However, its performance in metabolic dysfunction-associated steatotic disease (MASLD), particularly obese patients, remains to be explored. Methods This study evaluated the role of M2BPGi predicting fibrosis 205 patients with MASLD using magnetic resonance elastography (MRE) as reference. The was compared vibration-controlled transient (VCTE), FIB-4, APRI, and NFS. PNPLA3, TM6SF2, HSD17B13 polymorphisms were assessed by allelic discrimination assays. Results area under ROC curves VCTE, NFS differentiating significant 0.95 (95% CI; 0.91–0.98), 0.85 (0.79–0.92), 0.81 (0.74–0.89), 0.79 (0.71–0.87) 0.80 (0.72–0.87) (all P < 0.001), respectively. optimal cut-off values fibrosis, advanced cirrhosis 0.82, 0.95, 1.23 index (COI), yielding satisfactory sensitivity, specificity, diagnostic accuracy. consistent among subgroups according BMI, while AUROCs remarkably declined BMI ≥ 30 kg/m2. Patients PNPLA3 GG genotype had significantly higher than those CC/CG genotypes. In multivariate analysis, independent factors associated M2BPGi, rs738409. Conclusion Our data demonstrated that serum accurately across different indicating this could apply non-obese clinical settings.

Language: Английский

Diagnostic Performance of Serum Mac-2-Binding Protein Glycosylation Isomer as a Fibrosis Biomarker in Non-Obese and Obese Patients with MASLD DOI Creative Commons
Prooksa Ananchuensook,

Kamonchanok Moonlisarn,

Bootsakorn Boonkaew

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(2), P. 415 - 415

Published: Feb. 9, 2025

Background: Serum mac-2-binding protein glycosylation isomer (M2BPGi) is a new biomarker for liver fibrosis. However, its performance in metabolic dysfunction-associated steatotic disease (MASLD), particularly obese patients, remains to be explored. Methods: This study evaluated the role of M2BPGi predicting fibrosis 205 patients with MASLD using magnetic resonance elastography (MRE) as reference. The was compared vibration-controlled transient (VCTE), FIB-4, APRI, and NFS. PNPLA3, TM6SF2, HSD17B13 polymorphisms were assessed by allelic discrimination assays. Results: area under ROC curves VCTE, NFS differentiating significant 0.95 (95% CI; 0.91-0.98), 0.85 (0.79-0.92), 0.81 (0.74-0.89), 0.79 (0.71-0.87), 0.80 (0.72-0.87) (all p < 0.001), respectively. optimal cut-off values fibrosis, advanced cirrhosis 0.82, 0.95, 1.23 index (COI); yielding satisfactory sensitivity, specificity, diagnostic accuracy. consistent among subgroups according BMI, while AUROCs remarkably decreased BMI ≥ 30 kg/m2. Patients PNPLA3 GG genotype had significantly higher than those CC/CG genotypes. In multivariate analysis, independent factors associated M2BPGi, rs738409. Conclusions: Our data demonstrated that serum accurately across different indicating this could apply non-obese clinical settings.

Language: Английский

Citations

1

AI‐Based Platelet‐Independent Noninvasive Test for Liver Fibrosis in MASLD Patients DOI Creative Commons

Shun‐ichi Wakabayashi,

Takefumi Kimura,

Nobuharu Tamaki

et al.

JGH Open, Journal Year: 2025, Volume and Issue: 9(4)

Published: April 1, 2025

Noninvasive tests (NITs), such as platelet-based indices and ultrasound/MRI elastography, are widely used to assess liver fibrosis in metabolic dysfunction-associated steatotic disease (MASLD). However, platelet counts not routinely included Japanese health check-ups, limiting their utility large-scale screenings. Additionally, while effective, is costly less accessible routine practice. Most existing AI-based models incorporate these markers, restricting applicability. This study aimed develop a simple yet accurate AI model for staging using only demographic biochemical markers. retrospective analyzed biopsy-proven data from 463 MASLD patients. Patients were randomly assigned training (N = 370, 80%) test 93, 20%) cohorts. The incorporated age, sex, BMI, diabetes, hypertension, hyperlipidemia, blood markers (AST, ALT, γ-GTP, HbA1c, glucose, triglycerides, cholesterol). Support Vector Machine demonstrated high diagnostic performance, with an area under the curve (AUC) of 0.886 detecting significant (≥ F2). AUCs advanced F3) cirrhosis (F4) 0.882 0.916, respectively. Compared FIB-4, APRI, FAST score (0.80-0.96), SVM achieved comparable accuracy eliminating need count or elastography. accurately assesses patients without requiring Its simplicity, cost-effectiveness, strong performance make it well-suited screenings clinical use.

Language: Английский

Citations

0

Assessing the role of Mac-2 binding protein glycosylation isomer in the management of patients with chronic hepatitis B DOI Open Access

Thuy Thanh Pham,

Dat Tan Ho, Hai Thanh Phan

et al.

World Journal of Hepatology, Journal Year: 2025, Volume and Issue: 17(5)

Published: May 27, 2025

BACKGROUND The Mac-2 binding protein glycosylated isomer (M2BPGi) is a serum marker for fibrosis that correlates with the stages in various liver diseases. AIM To examine M2BPGi’s threshold staging patients chronic hepatitis B (CHB), and its changes during treatment. METHODS This was prospective, longitudinal study. A total of 348 eligible were recruited from Hepatology Department, Medic Medical Center between March 2020 December 2023. Liver enzyme tests, platelet counts, M2BPGi levels, FibroScan conducted at baseline 3-month intervals until six months post-treatment. Correlation plots M2BPGi, FibroScan, other parameters generated. Receiver operating characteristic curves constructed to evaluate their performance. RESULTS levels correlated well results increased as stage advanced. median different showed statistically significant differences. cut-off values diagnosing (F ≥ 2), advanced (F3), cirrhosis (F4) determined be 1.08, 1.4, 1.52, respectively. In context regression CHB first 6-month treatment, appeared decrease before this pattern occurred results. CONCLUSION strongly FibroScan. can used assess fibrosis, serve tool monitoring undergoing

Language: Английский

Citations

0

Hepatic Mac2‐BP expression depends on liver fibrosis and inflammation due to fat accumulation in patients with metabolic dysfunction‐associated steatotic liver disease DOI

Haruki Uojima,

Hanako Tsujikawa, Ken Yamazaki

et al.

Hepatology Research, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 10, 2024

Abstract Aim Data on the upregulation of Mac‐2 binding protein (M2BP) expression associated with fat accumulation in liver are limited. Therefore, we aimed to assess relationship between hepatic M2BP and changes microenvironment due patients metabolic dysfunction steatotic disease (MASLD). Methods Liver specimens obtained from 46 MASLD were subjected immunohistochemical staining visualize liver. The intensity hepatocytes sinusoidal cells was classified as high or low grade. First, correlation microenvironmental caused by examined. Then, influence serum glycosylation isomer levels evaluated. Results grade higher than ( p = 0.015). their had more severe lobular inflammation those 0.037). Additionally, presented fibrosis 0.018). correlated positively 0.023), whereas no observed 0.393). Conclusions Fat leads that fibrosis.

Language: Английский

Citations

1

Characteristics of diabetes mellitus patients with nonviral chronic liver disease who developed hepatocellular carcinoma DOI

Kyo Sasaki,

Miwa Kawanaka,

Yasuyuki Tomiyama

et al.

Hepatology Research, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 19, 2024

Abstract Aim Type 2 diabetes mellitus (T2DM) is a well‐known risk factor for hepatocellular carcinoma (HCC). However, HCC often diagnosed at an advanced stage in patients with because of the lack best criteria surveillance candidates. The aim this study was to identify factors development nonviral chronic liver disease. Method Three hundred thirty T2DM disease who underwent by imaging techniques between 2009 and 2020 were enrolled multicenter cross‐sectional retrospective study. clinical laboratory parameters without compared. Results Age ≥65 years, alcohol intake, hepatic steatosis, triglyceride level <111 mg/dL, Mac2 binding protein glycosylation isomer (M2BPGi) ≥0.9 cut‐off index (COI), α‐fetoprotein concentration ≥5 ng/mL, des‐γ‐carboxy prothrombin ≥26 mAU/mL independently associated development. When stratified age, only intake (odds ratio [OR] 114.19, p < 0.001) aged <65 medication (OR 5.72, = 0.001), steatosis 4.47, 0.002), lactate dehydrogenase ≥198 IU/L 2.751, 0.031), M2BPGi ≥1.18 COI 9.05, FIB‐4 ≥2.59 3.22, 0.017) years. Conclusions In addition age fibrosis, younger DM older should be considered imaging.

Language: Английский

Citations

1

Successful portosystemic shunt embolization resolves hepatic encephalopathy and enhances hepatic function and glycemic control in MASH-related cirrhosis: a case report DOI
Yoshiaki Kobayashi, Takanobu Iwadare, Hiroyuki Kobayashi

et al.

Clinical Journal of Gastroenterology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 23, 2024

Language: Английский

Citations

1

Exploring non-invasive diagnostics and non-imaging approaches for pediatric metabolic dysfunction-associated steatotic liver disease DOI
Toshifumi Yodoshi

World Journal of Gastroenterology, Journal Year: 2024, Volume and Issue: 30(47), P. 5070 - 5075

Published: Nov. 25, 2024

In this article, we comment on the article by Qu and Li, focusing specifically non-invasive diagnostic approaches for metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD is most common chronic in children. Nearly half of pediatric cases progress to steatohepatitis at diagnosis, often with comorbidities like renal disease, hypertension, type 2 diabetes, mental health disorders. Early diagnosis continuous intervention are crucial managing "silent organ" disease. Screening recommended children aged nine older obesity. Liver biopsy remains gold standard; however, due its invasiveness, methods - biomarkers, anthropometric algorithms, serum tests, imaging increasingly vital. This editorial provides an overview current or fibrosis.

Language: Английский

Citations

0

M2BPgs-HCC: An Automated Multilectin Bead Array Indicating Aberrant Glycosylation Signatures Toward Hepatitis C Virus-Associated Hepatocellular Carcinoma Prognosis DOI Creative Commons

Hiroko Shimazaki,

Haruki Uojima,

Kazumi Yamasaki

et al.

Molecules, Journal Year: 2024, Volume and Issue: 29(23), P. 5640 - 5640

Published: Nov. 28, 2024

Regular monitoring of patients with a history hepatitis C virus (HCV) infection is critical for the detection and management hepatocellular carcinoma (HCC). Mac-2 binding protein glycosylation isomer (M2BPGi) has been used to monitor fibrosis progression predict HCC. However, HCC prediction based on M2BPGi not optimized. Here, we identified risk-related glycan signatures M2BP using newly developed automated bead array multiplexed lectins. Among 955 HCV who achieved sustained virological response following direct-acting antiviral treatment, compared from sera 42 diagnosed during follow-up 43 without (control) by lectin microarray. At observation point, found significant differences in 17 Using an 12 lectins, principal component analysis (PCA) biplot differentiated control, along PC1 axis, explaining 75.2% variance. Based PC1, generated scoring formula HCC-related signature (M2BPgs-HCC), showing good diagnostic performance (

Language: Английский

Citations

0

Utility of Mac-2 binding protein glycosylation isomer as an excellent biomarker for the prediction of liver fibrosis, activity, and hepatocellular carcinoma onset: an expert review DOI
Yoshihiro Kamada, Yoshio Sumida,

Hirokazu Takahashi

et al.

Journal of Gastroenterology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 9, 2024

Language: Английский

Citations

0

Serum Mac2-binding protein glycosylated isomer (M2BPGi) as a prognostic biomarker in pancreatic ductal adenocarcinoma: iCAFs-derived M2BPGi drives tumor invasion DOI

Naotaka Kugiyama,

Katsuya Nagaoka, Rin Yamada

et al.

Journal of Gastroenterology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 11, 2024

Language: Английский

Citations

0